FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody which binds to human VEGF and to human IL-1beta, as well as to a method for production thereof. Also disclosed are recovered nucleic acid encoding said antibody, as well as a vector and a cell containing said nucleic acid.
EFFECT: invention is effective for treating vascular eye diseases.
11 cl, 14 dwg, 16 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
ANTIBODIES TO LAG3 | 2018 |
|
RU2778053C2 |
ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
Authors
Dates
2024-03-29—Published
2019-12-20—Filed